Key result
Female sex is linked to ~69% lower major cardiovascular events risk than men only without polyvascular disease.
Why the study?
While polyvascular disease exhibits worse outcomes, it remains unknown whether female sex impacts cardiovascular outcomes in patients with polyvascular disease.
Does female sex affect the 3-year risk of major adverse cardiovascular events (MACE) in coronary artery disease patients undergoing PCI with and without polyvascular disease?
Observational (n=678)
Yes
Does female sex affect the 3-year risk of major adverse cardiovascular events (MACE) in coronary artery disease patients undergoing PCI with and without polyvascular disease?
While female sex is protective against 3-year MACE among CAD patients undergoing PCI without polyvascular disease, this sex-related advantage is lost in patients with polyvascular disease, where women have higher on-treatment LDL-C levels and similar event rates to men, underscoring the need for intensified lipid-lowering management in both sexes.
Answers are grounded in this paper and cite their sources.
Polyvascular disease may negate female sex advantage in CAD; hypothesis-generating for sex-specific risk models.
Background: Sex differences exist in atherosclerotic cardiovascular disease, partly due to the anti-atherosclerotic properties of estrogens in women. While polyvascular disease (PolyVD) exhibits worse outcomes, it is unknown whether women have an impact on cardiovascular outcomes of PolyVD. Methods and Results: We analyzed 678 coronary artery disease patients receiving PCI. PolyVD was defined as the concomitance of ischemic stroke and/or lower extremity arterial disease (LEAD). The occurrence of 3-year major adverse cardiovascular events (MACE; i.e., all-cause death + non-fatal myocardial infarction + ischemic stroke + ischemic-driven non-culprit lesion revascularization + LEAD) was compared between men and women with and without PolyVD, respectively. Women accounted for 17.8% and 21.1% of patients with and without PolyVD, respectively (P=0.34). In patients without PolyVD, women presented marginally higher on-treatment low-density lipoprotein cholesterol (LDL-C) levels (101.5 vs. 93.0 mg/dL; P=0.05). However, women exhibited a lower 3-year MACE risk (adjusted hazard ratio [HR] 0.31; 95% confidence interval [CI] 0.11-0.88; P=0.02). In patients with PolyVD, women exhibited higher LDL-C levels (103.0 vs. 82.0 mg/dL; P=0.04). Furthermore, even after adjusting clinical demographics and risk factor control, the 3-year MACE risk did not differ between males and females (adjusted HR 0.67; 95% CI 0.29-1.57; P=0.36). Conclusions: Women without PolyVD were less likely to experience 3-year MACE, whereas cardiovascular outcomes in women with PolyVD were similar to men with PolyVD. These findings suggest a need to intensify anti-atherosclerotic management in both men and women with PolyVD.
No takes yet. Share an insight, caveat, or question.
Katasako-Yabumoto et al. (2025) conducted an observational in Coronary artery disease receiving percutaneous coronary intervention (n=678). Female sex (in patients with polyvascular disease) vs. Male sex was evaluated on 3-year major adverse cardiovascular events (MACE) (HR 0.67, 95% CI 0.29-1.57, p=0.36). Women without polyvascular disease had a lower risk of 3-year major cardiovascular events compared to men, whereas cardiovascular outcomes in women with polyvascular disease were similar to men.
Synapse has enriched 10 related papers. Consider them for comparative context: